Article
[New 'targeted therapy' for lung cancer].
Nederlands tijdschrift voor geneeskunde - 1 Jan 2011
Groen Harry J M, Hiltermann Thijo J N, Schuuring Ed, Timens Wim
Abstract excerpt
Patients with non-small cell lung cancer with specific mutations for which so-called 'targeted therapy' is available are likely to have a favourable tumour response. The first patient, a man aged 64 with an activating epidermal growth factor receptor (EGFR) mutation, had a longstanding tumour response on erlotinib, an EGFR tyrosine kinase inhibitor (TKI). After 16 months on treatment, there was still no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
